EE86 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisagenlecleucel CAR T-Cell Therapies for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.390
https://www.valueinhealthjournal.com/article/S1098-3015(23)00490-4/fulltext
Title :
EE86 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisagenlecleucel CAR T-Cell Therapies for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00490-4&doi=10.1016/j.jval.2023.03.390
First page :
Section Title :
Open access? :
No
Section Order :
11774